- Home
- ETNB
ETNB
89bio Inc.
as 12-18-2024 9:49am EST
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 867.4M | IPO Year: | 2019 |
| Target Price: | $30.33 | AVG Volume (30 days): | 800.5K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.00 - $16.63 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of 89bio Inc. (ETNB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PALEKAR ROHAN | ETNB | Chief Executive Officer | Dec 6 '24 | Buy | $7.89 | 5,000 | $39,450.00 | 471,236 | |
| PALEKAR ROHAN | ETNB | Chief Executive Officer | Nov 22 '24 | Buy | $8.35 | 10,000 | $83,500.00 | 471,236 | |
| Le-Nguyen Quoc | ETNB | See Remarks | Oct 30 '24 | Sell | $8.12 | 27,955 | $226,994.60 | 187,796 |
Latest 89bio Inc. News
ETNB Breaking Stock News: Dive into ETNB Ticker-Specific Updates for Smart Investing
Insider Monkey
14 days ago
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
GlobeNewswire
19 days ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
22 days ago
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
GlobeNewswire
a month ago
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
GlobeNewswire
a month ago
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
a month ago
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
a month ago
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire
a month ago
89bio to Participate in the UBS Global Healthcare Conference
Compare ETNB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ETNB 89bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.